Skip to main content

14-09-2018 | Oncology | Main feed | News


EMA supports encorafenib plus binimetinib combination

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization be given for the combination of encorafenib and binimetinib in patients with BRAF V600-mutated unresectable or metastatic melanoma.

The efficacy of the combined BRAF inhibitor and the MEK inhibitor regimen in this population was demonstrated by overall survival findings from the COLUMBUS trial.

The joint therapy has also been approved by the US FDA for this indication.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage